Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Masimo (NASDAQ: MASI) and Qualcomm Technologies have partnered to develop a next-generation smartwatch reference platform for OEMs building Wear OS by Google smartwatches. This collaboration combines Masimo’s clinically proven biosensing technologies with Qualcomm’s Snapdragon wearable platforms to enhance the wearable ecosystem. The platform will feature:
- Masimo’s health and wellness tracking tools
- High-performance, ultra-low power SoCs
- Advanced wireless and cellular communications
OEMs will benefit from production-ready designs, incorporating Masimo’s biosensing technology and Qualcomm’s Snapdragon platforms, enabling rapid market entry at scale. The platform will include Masimo’s Signal Extraction Technology (SET) and offer the same capabilities as Masimo W1 and upcoming Masimo Freedom wearables.
Masimo (NASDAQ: MASI) e Qualcomm Technologies hanno stretto una collaborazione per sviluppare una piattaforma di riferimento per smartwatch di nuova generazione destinata agli OEM che producono smartwatch con Wear OS di Google. Questa collaborazione unisce le tecnologie di biosensing clinicamente consolidate di Masimo con le piattaforme indossabili Snapdragon di Qualcomm per migliorare l’ecosistema dei dispositivi indossabili. La piattaforma includerà:
- Gli strumenti di monitoraggio della salute e del benessere di Masimo
- SoC ad alte prestazioni e ultra-basso consumo energetico
- Comunicazioni wireless e cellulari avanzate
Gli OEM trarranno vantaggio da design pronti per la produzione, che integrano la tecnologia di biosensing di Masimo e le piattaforme Snapdragon di Qualcomm, consentendo un rapido accesso al mercato su larga scala. La piattaforma includerà la Tecnologia di Estrazione del Segnale di Masimo (SET) e offrirà le stesse funzionalità degli indossabili Masimo W1 e dei futuri dispositivi Masimo Freedom.
Masimo (NASDAQ: MASI) y Qualcomm Technologies se han aliado para desarrollar una plataforma de referencia de smartwatch de próxima generación para OEMs que construyen smartwatches con Wear OS de Google. Esta colaboración combina las tecnologías de biosensores clínicamente probadas de Masimo con las plataformas portátiles Snapdragon de Qualcomm para mejorar el ecosistema de dispositivos portátiles. La plataforma contará con:
- Herramientas de seguimiento de salud y bienestar de Masimo
- SOC de alto rendimiento y ultra-bajo consumo
- Comunicaciones inalámbricas y celulares avanzadas
Los OEM se beneficiarán de diseños listos para producción, incorporando la tecnología de biosensores de Masimo y las plataformas Snapdragon de Qualcomm, lo que permitirá una rápida entrada al mercado a gran escala. La plataforma incluirá la Tecnología de Extracción de Señales de Masimo (SET) y ofrecerá las mismas capacidades que los dispositivos Masimo W1 y los próximos dispositivos Masimo Freedom.
Masimo (NASDAQ: MASI)와 Qualcomm Technologies는 Google의 Wear OS 스마트워치를 제작하는 OEM을 위한 차세대 스마트워치 참조 플랫폼을 개발하기 위해 협력했습니다. 이번 협력은 Masimo의 임상적으로 검증된 바이오센싱 기술과 Qualcomm의 Snapdragon 웨어러블 플랫폼을 결합하여 웨어러블 생태계를 강화합니다. 이 플랫폼은 다음과 같은 기능을 갖추게 됩니다:
- Masimo의 건강 및 웰빙 추적 도구
- 고성능, 초저전력 시스템온칩(SoC)
- 진보된 무선 및 셀룰러 통신
OEM은 Masimo의 바이오센싱 기술과 Qualcomm의 Snapdragon 플랫폼을 통합한 생산 준비 완료 디자인으로 혜택을 볼 수 있으며, 이를 통해 대규모 시장 진입이 가능해집니다. 이 플랫폼은 Masimo의 신호 추출 기술(SET)을 포함하고, Masimo W1 및 향후 Masimo Freedom 웨어러블과 동일한 기능을 제공할 것입니다.
Masimo (NASDAQ: MASI) et Qualcomm Technologies se sont associés pour développer une plateforme de référence de smartwatch de nouvelle génération à destination des OEM construisant des smartwatches sous Wear OS de Google. Cette collaboration allie les technologies de biosensing cliniquement prouvées de Masimo aux plateformes portables Snapdragon de Qualcomm pour améliorer l’écosystème des appareils portables. La plateforme comprendra :
- Les outils de suivi de la santé et du bien-être de Masimo
- Des SoC haute performance et ultra-basse consommation
- Des communications sans fil et cellulaires avancées
Les OEM bénéficieront de conceptions prêtes à la production, intégrant la technologie de biosensing de Masimo et les plateformes Snapdragon de Qualcomm, permettant une entrée rapide sur le marché à grande échelle. La plateforme inclura la Technologie d’Extraction de Signal (SET) de Masimo et offrira les mêmes capacités que le Masimo W1 et les futurs appareils Masimo Freedom.
Masimo (NASDAQ: MASI) und Qualcomm Technologies haben sich zusammengeschlossen, um eine Referenzplattform für Smartwatches der nächsten Generation für OEMs zu entwickeln, die Wear OS von Google verwenden. Diese Zusammenarbeit kombiniert die klinisch bewährten Biosensing-Technologien von Masimo mit den tragbaren Snapdragon-Plattformen von Qualcomm, um das Ökosystem der tragbaren Geräte zu verbessern. Die Plattform wird Folgendes bieten:
- Masimos Gesundheits- und Wellness-Tracking-Tools
- Hochleistungs-SoCs mit extrem niedrigem Stromverbrauch
- Fortschrittliche drahtlose und zellulare Kommunikation
OEMs profitieren von produktionsbereiten Designs, die die Biosensing-Technologie von Masimo und die Snapdragon-Plattformen von Qualcomm integrieren, was einen schnellen Markteintritt in großem Maßstab ermöglicht. Die Plattform wird die Signalk Extraction Technologie (SET) von Masimo umfassen und die gleichen Funktionen wie die Masimo W1 und die kommenden Masimo Freedom Wearables bieten.
Positive
- Partnership with Qualcomm to develop next-generation smartwatch reference platform
- Expansion into the growing wearable technology market
- Potential for increased revenue through OEM adoption of the reference platform
- Leveraging Masimo’s clinically proven biosensing technologies in consumer wearables
This partnership between Masimo and Qualcomm represents a significant technological advancement in the smartwatch industry. By combining Masimo’s expertise in biosensing with Qualcomm’s Snapdragon platforms, the reference design could accelerate innovation and improve performance of Wear OS devices. The collaboration addresses key challenges in wearable technology:
- Enhanced health monitoring capabilities
- Improved power efficiency
- Streamlined development process for OEMs
This could potentially disrupt the smartwatch market, offering OEMs a competitive edge against established players like Apple and Samsung. However, success will depend on how well OEMs leverage this platform and differentiate their products in a crowded market.
This partnership has significant market implications. By providing a comprehensive reference platform, Masimo and Qualcomm are lowering barriers to entry for new players in the smartwatch market. This could lead to:
- Increased competition and innovation
- Potential market share shifts
- Expansion of the Wear OS ecosystem
The collaboration might also challenge Apple’s dominance in the health-focused wearables segment. However, the impact on Masimo’s core medical device business and how this venture aligns with their long-term strategy remains to be seen. Investors should monitor how this affects Masimo’s revenue streams and market positioning in both consumer and medical sectors.
While the partnership shows promise, its financial impact remains uncertain. Key considerations for investors include:
- Potential revenue streams from licensing or royalties
- R&D costs associated with platform development
- Long-term market adoption rates
Masimo’s expansion into consumer wearables represents a diversification strategy, potentially reducing reliance on medical device sales. However, this move also exposes the company to new competitive pressures and market dynamics. The success of this venture will likely depend on OEM adoption rates and the performance of end products in the market. Investors should closely monitor future financial reports for signs of revenue growth or margin impacts resulting from this initiative.
Comprehensive Platform Combines Masimo’s Industry-leading Biosensing Capabilities with Snapdragon Wearable Platforms to Expand the Wear OS by Google™ Ecosystem
IRVINE, Calif.–(BUSINESS WIRE)– Masimo (NASDAQ: MASI), a leading global medical innovator, and Qualcomm Technologies, Inc., whose Snapdragon® branded platforms power extraordinary consumer experiences, today announced that Masimo is partnering with Qualcomm Technologies to develop a next-generation smartwatch reference platform for original equipment manufacturers (OEMs) building Wear OS by Google smartwatches. The powerhouse combination of Masimo’s clinically proven, breakthrough biosensing technologies – based on its decades of expertise designing industry-leading hospital monitoring solutions – and best-in-class Snapdragon wearable platforms will help scale the wearable ecosystem. Forging the future of wearable devices, the reference platform will allow OEMs to more efficiently build and bring high-performing, premium smartwatches to market. The platform will also benefit from a robust suite of Masimo health and wellness tracking tools that consumers can trust to provide accurate, reliable data; it will use exclusively high-performance and ultra-low power system-on-a-chips (SoCs) alongside industry-leading wireless and cellular communications from Qualcomm Technologies to enable a superior connectivity experience.
Qualcomm Technologies and Masimo (Photo: Business Wire)
Joe Kiani, Founder and CEO of Masimo, said, “We’re thrilled to be able to partner with Qualcomm Technologies, to whom we naturally turned to supply the chips in our own forthcoming Masimo Freedom™ wearable, to craft a truly remarkable reference platform. It’s a platform driven by the belief that when key smartwatch components are supplied by the leading experts in their field, the harmonious whole produces something even greater than the sum of those excellent parts. In short, Qualcomm Technologies and Masimo engineers are working together to optimize the ‘guts’ of the smartwatch. Masimo’s ability to craft precision monitoring technologies and advanced signal processing algorithms, combined with meticulously engineered, high-performing, low-power Snapdragon systems, is a compelling foundation. We expect this new wearable platform to supercharge smartwatch OEMs’ abilities to create competitive, desirable smartwatches for consumers everywhere. I look forward to partnering with a company as well known for its commitment to innovation as Masimo.”
Dino Bekis, Vice President and General Manager, Wearables and Mixed Signal Solutions at Qualcomm Technologies, Inc., said, “Beginning with Snapdragon W5+ Gen 1, this collaboration will significantly broaden the range of smartwatch choices for consumers and further enhance the already exceptional Wear OS experience. With these reference designs, OEMs will benefit from robust, production-ready designs, incorporating Masimo’s state-of-the-art biosensing technology and Qualcomm Technologies’ leading Snapdragon wearable platforms. It will ultimately enable them to seamlessly bring their smartwatches to market rapidly and at scale.”
OEMs who adopt the new reference platform will continue to design and produce their new smartwatches’ physical exteriors and have creative control over the appearance of the user interface. The devices’ interiors, including Snapdragon wearable platforms and Masimo biosensors, will be designed, provided, and tested by Masimo to ensure premium performance and an unmatched user experience. Health and wellness capabilities will feature the same biosensing innovations and analytics that power Masimo W1® and forthcoming Masimo Freedom – technology based on Masimo’s clinically proven, industry-leading Signal Extraction Technology® (SET®). The Masimo reference platform will make all of these components, features, and benefits available for Wear OS smartwatch manufacturers in an easy-to-implement, standardized package.
Snapdragon is a trademark or registered trademark of Qualcomm Incorporated. Snapdragon is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
Wear OS by Google is a trademark of Google LLC.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-5 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2024 Newsweek World’s Best Hospitals listing.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97® and the Masimo W1® Medical Watch. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius Tº® and Masimo W1 Sport. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.
References
- Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar.
- Estimate: Masimo data on file.
- https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states
Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the future development, efficiency, potential performance and adoption of the new Masimo reference platform (the “Platform”) and Masimo’s collaboration with Qualcomm. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo’s unique noninvasive measurement technologies, including the Platform, contribute to accurate, reliable data; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to the assumption that the Platform will be available for integration into future OEM smartwatches; risks related to our belief that the Platform and OEMs will benefit from the collaboration with Qualcomm; risks related to COVID-19; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240914175461/en/
Masimo
Evan Lamb
949-396-3376
Source: Masimo
FAQ
What is the purpose of Masimo’s partnership with Qualcomm for MASI stock?
The partnership aims to develop a next-generation smartwatch reference platform for OEMs building Wear OS by Google smartwatches, potentially expanding Masimo’s market presence and revenue streams in the wearable technology sector.
How will the Masimo-Qualcomm smartwatch platform benefit OEMs?
OEMs will benefit from production-ready designs incorporating Masimo’s biosensing technology and Qualcomm’s Snapdragon platforms, enabling them to bring smartwatches to market rapidly and at scale.
What technologies will be included in the Masimo-Qualcomm smartwatch reference platform?
The platform will include Masimo’s Signal Extraction Technology (SET), health and wellness tracking tools, high-performance ultra-low power SoCs, and advanced wireless and cellular communications from Qualcomm.
When will the Masimo-Qualcomm smartwatch reference platform be available for OEMs?
The press release does not specify a release date for the smartwatch reference platform. It appears to be in development, with no specific timeline provided.
